Featured Research

from universities, journals, and other organizations

Improving Survival Rates Among Users Of Left Ventricular Assist Devices

Date:
April 30, 2008
Source:
Wiley-Blackwell
Summary:
Despite the general success of left ventricular assist devices used in critically ill heart failure patients, implantation of these devices often leads to increased bleeding and a need for high-volume blood transfusions during and immediately after surgery.

Despite the general success of left ventricular assist devices (LVADs) used in critically ill heart failure patients, implantation of these devices often leads to increased bleeding and a need for high-volume blood transfusions during and immediately after surgery. A new study published in Artificial Organs provides data suggesting that the incidence of these complications may be significantly reduced by way of a single plasma exchange before surgery.

Patients in need of LVAD implantation usually have an abnormal coagulation profile, which can increase the chances of hemorrhagic complications after surgery. To optimize the coagulation profiles of LVAD patients, and thereby reduce the risk of complications, the study suggests replacing 1 plasma volume using fresh frozen plasma as the substitution fluid prior to surgery.

According to this single-center study, a series of patients who underwent plasma exchange before LVAD implantation had notably better survival rates than those who did not. These results were consistent both 7 and 30 days after insertion.

“Given the relatively benign nature of this intervention and the low risk posed, we believe that plasma exchange may be considered a treatment option for these high-risk patients,” says lead author Rajko Radovancevic, senior research scientist at the Texas Heart Institute.


Story Source:

The above story is based on materials provided by Wiley-Blackwell. Note: Materials may be edited for content and length.


Cite This Page:

Wiley-Blackwell. "Improving Survival Rates Among Users Of Left Ventricular Assist Devices." ScienceDaily. ScienceDaily, 30 April 2008. <www.sciencedaily.com/releases/2008/04/080430120741.htm>.
Wiley-Blackwell. (2008, April 30). Improving Survival Rates Among Users Of Left Ventricular Assist Devices. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2008/04/080430120741.htm
Wiley-Blackwell. "Improving Survival Rates Among Users Of Left Ventricular Assist Devices." ScienceDaily. www.sciencedaily.com/releases/2008/04/080430120741.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins